ERBB2 and breast carcinoma: We recently reported the interim analysis results of a real-world, multi-center, observational cohort study to evaluate real-world effectiveness of palbociclib in HR+/HER2– ABC patients in Japan; P-BRIDGE study (Palbociclib in Japan: Breast cancer Real-world Investigation of DruG utilization and Effectiveness; NCT05399329) [15].